VVD-118313
Overview of the experimental drug VVD-118313
VVD-118313[edit | edit source]
VVD-118313 is an experimental drug that has been investigated for its potential therapeutic effects in the treatment of various neurological disorders. It is a small molecule that acts as a selective antagonist of the 5-HT6 receptor, a subtype of the serotonin receptor family. The compound was developed with the aim of improving cognitive function and has been studied primarily in the context of Alzheimer's disease and other forms of dementia.
Pharmacology[edit | edit source]
VVD-118313 functions by selectively binding to and inhibiting the activity of the 5-HT6 receptor. This receptor is predominantly expressed in the central nervous system, particularly in regions of the brain associated with learning and memory, such as the hippocampus and cortex. By blocking the 5-HT6 receptor, VVD-118313 is thought to enhance the release of neurotransmitters like acetylcholine, dopamine, and glutamate, which play crucial roles in cognitive processes.
Mechanism of Action[edit | edit source]
The 5-HT6 receptor is a G protein-coupled receptor (GPCR) that is positively coupled to adenylate cyclase, leading to an increase in cyclic AMP (cAMP) levels when activated. By antagonizing this receptor, VVD-118313 reduces cAMP production, which in turn modulates neurotransmitter release and neuronal signaling pathways. This modulation is believed to contribute to the cognitive-enhancing effects observed in preclinical studies.
Potential Therapeutic Applications[edit | edit source]
VVD-118313 has been primarily investigated for its potential use in treating cognitive deficits associated with Alzheimer's disease. Preclinical studies have shown that the compound can improve performance in animal models of memory impairment. Additionally, there is interest in exploring its use in other conditions characterized by cognitive dysfunction, such as schizophrenia and Parkinson's disease.
Development and Research[edit | edit source]
The development of VVD-118313 is part of a broader effort to create novel treatments for cognitive disorders by targeting the serotonergic system. While the compound has shown promise in early-stage research, further studies are needed to fully understand its efficacy and safety profile in humans. Clinical trials are necessary to determine the optimal dosing, potential side effects, and long-term benefits of VVD-118313.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
